Ignite Creation Date:
2024-05-06 @ 3:32 AM
Last Modification Date:
2024-10-26 @ 11:35 AM
Study NCT ID:
NCT02313272
Status:
COMPLETED
Last Update Posted:
2023-10-23
First Post:
2014-12-05
Brief Title:
Hypofractionated Stereotactic Irradiation HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Phase I Trial of Hypofractionated Stereotactic Irradiation HFSRT With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
Status:
COMPLETED
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to see if the addition of the investigation drug called pembrolizumab Keytruda to radiation therapy and bevacizumab Avastin is safe and can help with controlling the growth of tumors in participants with recurrent high grade glioma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None